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ABSTRACT  
 
Purpose: Cisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom 
perception of sound. Our purpose was to identify the clinical and genetic determinants of 
tinnitus among testicular cancer survivors (TCS) following cisplatin-based chemotherapy. 
 
Experimental Design: TCS (n= 762) were dichotomized to cases (moderate/severe 
tinnitus; n=154) and controls (none; n=608). Logistic regression was used to evaluate 
associations with comorbidities and SNP dosages in GWAS following quality control and 
imputation (covariates: age, noise exposure, cisplatin dose, genetic principal components). 
Pathway over-representation tests and functional studies in mouse auditory cells were 
performed. 
 
Results: Cisplatin-induced tinnitus (CisIT) significantly associated with age at diagnosis 
(P=0.007) and cumulative cisplatin dose (P=0.007). CisIT prevalence was not significantly 
greater in 400 mg/m2-treated TCS compared to 300 (P=0.41), but doses >400 mg/m2 
(median 580, range 402-828) increased risk by 2.61-fold (P<0.0001). CisIT cases had 
worse hearing at each frequency (0.25-12 kHz, P<0.0001), and reported more vertigo 
(OR=6.47; P<0.0001) and problems hearing in a crowd (OR=8.22; P<0.0001) than controls. 
Cases reported poorer health (P=0.0005) and greater psychotropic medication use 
(OR=2.4; P=0.003). GWAS suggested a variant near OTOS (rs7606353, P=2x10-6) and OTOS 
eQTLs were significantly enriched independently of that SNP (P=0.018). OTOS 
overexpression in HEI-OC1, a mouse auditory cell line, resulted in resistance to cisplatin-
induced cytotoxicity. Pathway analysis implicated potassium ion transport (q=0.007). 
 
Conclusions: CisIT associated with several neuro-otological symptoms, increased use of 
psychotropic medication, and poorer health. OTOS,  expressed in the cochlear lateral wall, 
was implicated as protective. Future studies should investigate otoprotective targets in 
supporting cochlear cells. 
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TRANSLATIONAL RELEVANCE  
 
Cisplatin is one of the most commonly prescribed chemotherapeutics worldwide, but elicits 
several debilitating off-target toxicities, including cisplatin-induced tinnitus (CisIT; a 
perceived ringing/buzzing noise with no external sound present). CisIT significantly affects 
perceived quality of life, but its etiology remains poorly understood. We found that 
cumulative cisplatin doses exceeding 400 mg/m2 to markedly increase CisIT susceptibility, 
and that survivors with tinnitus were more likely to experience hearing loss, vertigo, and 
problems hearing in a crowd, as well as report poorer health and greater reliance on 
psychotropic medication. Through a genome-wide association study, we identified genetic 
variants in OTOS, a gene vital for the maintenance of normal hearing, to be associated with 
CisIT, and further demonstrated that increased OTOS expression was associated with 
reduced cisplatin sensitivity in silico and in vitro. These data provide novel mechanistic 
insights into CisIT susceptibility, and may inform clinicians of potential risk factors and 
comorbidities. 
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INTRODUCTION 
 
Approximately 9.6% of the U.S. population experiences tinnitus, the phantom perception of 
sound characterized by persistent ringing, buzzing, beeping, or hissing in the ears (1). 
Several studies have linked tinnitus to increased anxiety, depression, insomnia, and 
reduced productivity and quality of life (QoL) (2, 3). Nevertheless, the pathogenic 
mechanisms of this disorder remain poorly understood (4), and no pharmacological agents 
are approved to treat tinnitus (5); treatment is typically limited to cognitive behavioral 
therapy and management of associated anxiety (5, 6). Despite its etiological ambiguity, 
several risk factors have been shown to contribute to the development of tinnitus, 
including age, hearing loss, and the administration of ototoxic drugs (7, 8). 
 
Cisplatin is one of the most commonly used chemotherapeutics, and is known for its potent 
ototoxic effects. It can lead to irreversible bilateral hearing loss in up to 80% of patients, 
with many experiencing permanent tinnitus (9-11).  Although few studies have rigorously 
assessed tinnitus following cisplatin-based chemotherapy, approximately 40% of patients 
appear to experience at least some degree of tinnitus [6]. This is substantially higher than 
the rate observed in the general U.S. population, and in testicular cancer patients who did 
not receive cisplatin-based chemotherapy (12%; [9]). Severe cases of tinnitus are also 
markedly increased in cisplatin-treated patients when compared to the general population 
(22% vs. 1-2%) (4) (9). One study of 1,409 testicular cancer survivors (TCS) noted that 
19% of TCS treated with 100-400 mg/m2 cisplatin exhibited symptoms of moderate/severe 
tinnitus, with that prevalence reaching 42% in the dose-intensive cisplatin chemotherapy 
group [9], suggesting a dose-dependent effect. It has been previously demonstrated that 
cancer survivors with neuropathy, hearing loss, and tinnitus were more likely to report 
poorer quality of life (QoL) than those with neuropathy alone (12). Another investigation 
confirmed worse perceived stress among cancer survivors with tinnitus (13).  
 
Despite this documented effect on QoL, little is known about the risk factors and 
mechanisms of cisplatin-induced tinnitus (CisIT). The subjective nature of the disorder and 
lack of model systems hamper the elucidation of its pathophysiology. While genotype-
phenotype associations promise to identify underlying molecular alterations, to our 
knowledge, no genome-wide association study (GWAS) of CisIT has yet been conducted. We 
previously characterized ototoxicity in our North American cohort of TCS receiving 
homogeneous cisplatin-based treatment. Among 488 TCS, 40% experienced some degree of 
tinnitus and 15.8% reported moderate/severe tinnitus. Further, tinnitus was significantly 
correlated with reduced hearing at each frequency examined (P < 0.001) (9). In this study, 
we comprehensively evaluate the role of clinical characteristics and modifiable risk factors 
on the development of tinnitus after cisplatin-based chemotherapy in a cohort of 762 TCS, 
and identify genetic determinants of CisIT through GWAS. In addition, we conduct pathway 
analyses and in vitro experiments to validate and contextualize our results.  
METHODS 
 
Patients and Study Design 
All patients were enrolled in the Platinum Study, which includes eight cancer centers in the 
United States and Canada. Eligibility criteria included: men diagnosed with histologically or 
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serologically confirmed germ cell tumor (GCT), age <55 years at diagnosis and >18 years at 
enrollment, treatment with first-line cisplatin-based chemotherapy regimen for either 
initial GCT or recurrence after active surveillance, with no antecedent chemotherapy for 
another primary cancer, no salvage chemotherapy, and routine follow-up at the 
participating site. All patients were disease-free at the time of clinical evaluation and 
provided written consent for study participation, access to medical records, and 
genotyping. Study procedures were approved by the Human Subjects Review Board at each 
institution. The studies were conducted in accordance with the U.S. Common Rule. 
 
Assessments 
Patient data were either ascertained at clinical follow-up or abstracted from medical 
records according to a standardized protocol (Figure S1). Data abstracted from medical 
charts included age at GCT diagnosis, GCT tumor characteristics, treatment regimen with 
cumulative dose and number of cycles, and BMI at the initiation of treatment. Data 
collected at clinical evaluation included age and BMI, audiometric studies, self-reported 
questionnaires, and genotyping. Pure-tone air conduction thresholds were measured 
bilaterally on a subset of 602 survivors at the frequency range 0.25-12 kHz to quantify 
hearing. The geometric mean of hearing thresholds across cisplatin-affected frequencies 
(4-12 kHz) was used to quantify cisplatin-induced hearing loss as previously described (9). 
Self-reported ototoxicity and neurotoxicity were assessed with two validated 
questionnaires: the EORTC-Chemotherapy Induced Peripheral Neuropathy 20 item 
questionnaire (CIPN20) and the Scale for Chemotherapy-Induced Neurotoxicity (SCIN)(14).  
 
Hypertension, hypercholesterolemia, use of psychotropic medication (antidepressants, 
anxiolytics, and antipsychotics), overall health, tobacco use, alcohol consumption, and noise 
exposure were also ascertained at follow-up as patient-reported outcomes. Hypertensive 
subjects indicated receiving a diagnosis of high blood pressure and taking prescription 
medication for it at evaluation. Hypercholesterolemia subjects answered “yes, current” to 
the question: “Have you ever taken prescription medication for high cholesterol?” The use 
of psychotropic medication was assessed as in Fung et al. (15), and was based on whether a 
patient had been taking psychotropic medication for at least one month at the time of 
clinical evaluation. Self-reported health was rated on a poor-excellent scale in response to 
the question “How would you rate your health?” Values were numerically converted for 
association testing (poor/fair = 1, good = 2, very good = 3, excellent = 4). Exposure to noise 
was assessed using two questions: “Have you ever had a job where you were exposed to 
loud noise for 5 or more hours a week? (Loud noise means noise so loud that you had to 
speak in a raised voice to be heard)” and “Outside of a job, have you ever been exposed to 
steady loud noise or music for 5 or more hours a week? (Examples are noise from power 
tools, lawn mowers, farm machinery, cars, trucks, motorcycles, or loud music)”. After 
numeric conversion (Yes = 1, No = 0), overall noise exposure was computed as the sum of 
noise exposure in and outside of work. Alcohol consumption was assessed as the self-
reported response to the question “During the past year, how many drinks of alcoholic 
beverage have you consumed on average? (1 drink = 12 oz. beer [1 can or bottle], 4 oz. 
glass of wine, 1 mixed drink or shot of liquor)” with the following options: Rarely/never 
(0), 1-3/month (1), 1/week (2), 2-4/week (3), 5-6/week (4), 1/day (5), 2-3/day (6), 4-
5/day (7), and 6+/day (8). Tobacco use was assessed as the response to the following two 
Research. 
on April 30, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3179 
6 
 
questions: “Have you EVER smoked cigarettes?” with “Yes” (1) and “No” (0) options and 
“Do you CURRENTLY smoke cigarettes?” 
 
Genotyping 
Genotyping was done as previously described (16, 17). DNA was extracted from peripheral 
blood mononuclear cells. SNPs were genotyped in two phases at the RIKEN Center for 
integrative Medical Science (Yokohama, Japan). Set 1 was genotyped on the 
HumanOmniExpressExome-8v1-2_A chip (Illumina, San Diego, CA) and set 2 was 
genotyped on the InfiniumOmniExpressExome-8v1-3_A chip (Illumina, San Diego, CA). 
Samples were plated with inter- and intra-plate duplicates at random. Standard quality 
control (QC) was implemented in PLINK, and is outlined in Figure S2. Sample-level QC 
criteria included: sample call rate > 0.99, pairwise identity by descent < 0.125, coefficient of 
inbreeding F < 6 standard deviations from the mean, and genetically European as 
determined by principal component analysis (performed using SMARTPCA). SNP-level QC 
included: call rate > 0.99, and Hardy-Weinberg equilibrium (Chi-squared P > 1 x 10-6). QC 
was first performed in each set independently and then the two sets were merged followed 
by additional QC. QC for batch effects was performed using a batch pseudo-GWAS where 
variants associated with batch pseudo-phenotype (10 genotypic PC-adjusted P<10-4) were 
excluded. SNPs and samples passing QC criteria comprised the input set for imputation 
with EAGLE phasing, performed on the Michigan Imputation Server using the Haplotype 
Reference Consortium (18-20). SNPs with imputation R2 < 0.8, MAF < 0.01, and INFO scores 
> 1.05 or < 0.3 were excluded. Only subjects who passed QC were included in the current 
study (Figure S2).  
 
Case-Control Definition 
Using SCIN (14), TCS were dichotomized to tinnitus cases/controls based on responses to 
the question: “Have you had in the last 4 weeks: Ringing or buzzing in the ears?” Cases 
responded “quite a bit/very much”, and controls responded “not at all”. Those answering “a 
little” were not included. We labeled “not at all”, “a little”, and “quite a bit/very much” as 
none, mild, and moderate/severe tinnitus.  TCS were also asked: “Do you have: ringing and 
buzzing in the ears?” Tinnitus cases responding “no” to this question were excluded from 
analysis. 
 
Genome-Wide Analyses 
GWAS was done in PLINK v1.9 (21, 22) with logistic regression assuming additive effects, 
with cumulative cisplatin dose, age at diagnosis, self-reported noise exposure, and the first 
5 genetic principal components (SMARTPCA (23)) as covariates. We performed imputation 
of missing covariates to avoid sample exclusion. Eight individuals with missing age at 
diagnosis were assigned an imputed age calculated as age at clinical follow-up minus 
median follow-up duration (5.2 years). Twelve individuals were missing values for 
cumulative cisplatin dose received, but each of these patients had information on the cycles 
of cisplatin received. Since one cycle of cisplatin is equivalent to 100 mg/m2, these patients 
were assigned an imputed cumulative dose by multiplying the number of cycles they 
received by 100 (i.e. 3 cycles x 100 = 300 mg/m2). No subjects were missing data on noise 
exposure. Genome-wide significance was set to P<5 x 10-8. A list of expression quantitative 
trait loci (eQTLs) was extracted from GTEx v7 using all 48 tissues with eQTL analysis (24). 
Research. 
on April 30, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3179 
7 
 
Conditional analysis was performed by adjusting for the lead single nucleotide 
polymorphism (SNP) as a covariate. SNP family enrichment was assessed using the 
empirical Brown’s combined p-value (25). Narrow-sense heritability was estimated with a 
genetic relationship matrix variance component model as implemented by GCTA with the 
same covariates as GWAS (26). Pathway over-representation analysis was performed using 
Gene Ontology (27, 28) pathways with the g:Profiler package(29) at a significance 
threshold of FDR q < 0.05 after attributing genes the p-value of the most significantly 
associated SNP in or within 25 kilobases of gene start/end sites (GENCODE GRCh37.p12).  
 
Gene Expression and Toxicity in Cell Lines 
OTOS expression data in different cancer cell lines was obtained from the Cancer Cell Line 
Encyclopedia (CCLE) (30). Drug sensitivity to cisplatin and other antineoplastic agents, 
measured as the area under the dose-response curve, was obtained from the Genomics of 
Drug Sensitivity in Cancer Project (31). Spearman correlation and linear regression was 
performed between expression and sensitivity of cancer cell lines with non-missing OTOS 
expression in R 3.3.2. 
 
Statistical Analysis 
Data are presented with medians (ranges). Age was modeled continuously and in quartiles 
(ordinal). Cisplatin dose was treated continuously and in dose categories: <300, 300, 400, and 
>400 mg/m2. Prevalence ratios (PR) were calculated to compare tinnitus prevalence by treatment 
or allele group, with normal approximation for 95% confidence intervals (CI) and χ2 p-values 
reported. Logistic models were constructed to assess associations (odds ratios [OR]) with tinnitus 
in univariable and multivariable contexts. All tests were two-sided at a significance threshold of 
P<0.05. Results are presented as OR/PR (95% CI). All statistical analyses were performed in R 
3.3.2 and plotted with ggplot2 (32) unless otherwise specified.  
 
Cell Culture 
HEI-OC1, a mouse auditory cell line derived from the inner ear organ of Corti, was cultured 
in complete media of DMEM (high glucose, L-glutamine and pyruvate) with 10% FBS 
(Corning Inc.; Tewksbury, MA). L929, a mouse fibroblast cell line, was cultured in complete 
media of EMEM with 10% FBS and 1% penicillin/ streptomycin.  Cells were passaged 3-
times/week, plated at 1 x 106 cells/T25 culture flask, and grown in a humidified chamber. 
HEI-OC1 was grown at 33oC with 10% CO2 and L929 at 37oC with 5% CO2. The authenticity 
of the cell lines was confirmed by IDEXX BioResearch (Columbia, MO) by measurement for 
interspecies contamination or misidentification, Case # 26495-2018 (HEI-OC1) and  
#32923-2018 (L929). Cell lines were also assessed for mycoplasma contamination using a 
MycoAlert Mycoplasma Detection Kit (Lonza; Rockland, ME) at the time of acquisition and 
prior to performing in vitro experiments. 
 
Plasmid Preparation 
OTOS protein vector, pOTOS (pPM-N-D-C-His; cat# PV401573) and blank control 
(pControl; PV001) vector were purchased from Applied Biological Materials, Inc. 
(Richmond, BC), with the blank control vector sequence being verified by the supplier. The 
plasmids were amplified into competent DH5α bacteria (Life Technologies Corporation; 
Grand Island, NY), expanded using 50µg/ml kanamycin selection, and isolated using 
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PureYield Plasmid Midiprep (Promega Corporation; Madison, WI). Confirmation of OTOS 
cDNA sequence was performed at the University of Chicago DNA Sequencing Core.  
 
Cell Viability Assay 
After 24 hours of plating each cell line at 31,250 cells/cm2 into 96-well plates, the cells 
were transfected in Opti-MEM (Life Technologies) with the addition of a complexed DNA 
mixture consisting of 1 part Lipofectamine 3000 (Fisher Scientific) with 3 μg pOTOS or 
pControl, as per manufactures’ instructions. Transfection continued for 24 hours. Cisplatin 
(Sigma-Aldrich) was dissolved in a darkened hood using 0.9% saline. The solution was 
vortexed for 1 minute, sonicated for 10 minutes with no heat, and then filtered through a 
0.2 µm syringe filter to obtain a 10 mM stock solution. Transfection media was exchanged 
for 5, 7.5, 10, 25 or 50 μM cisplatin in complete media or vehicle control. At 48 or 72 hours 
post-drug treatment, 100 uL CellTiter-Glo (Promega Corporation) was added to each well, 
as per manufacturer’s instructions. 135 μL of each well was transferred to a white Costar 
assay plate (Fisher Scientific) and luminescence was measured on a Synergy-HT plate 
reader (BioTek Corporation; Broadview, IL). Four independent experiments were 
performed and within an experiment, each concentration was evaluated in triplicate. IC50 
values were calculated through non-linear regression of the log cisplatin concentration vs. 
normalized response curve using Prism6 software. 
 
Quantitative PCR. 
Cells were plated at 31,250 cells/cm2 into 12-well plates for qPCR collections. After 24, 48, 
72, and 96 hours of transfection (corresponding to 0, 24, 48, and 72 hours after cisplatin 
treatment), cells were pelleted following a brief trypsinization and stored at -80oC.  RNA 
was isolated using the RNeasy Plus Kit (Qiagen; Germantown, MD) followed by reverse 
transcription of 200ng RNA into cDNA with the High Capacity cDNA reverse transcription 
kit (Fisher Scientific). Mouse OTOS (Mm01292235_g1) expression was tested in HEI-OC1 
and L929 cells, and was found to be minimally expressed. Expression of human OTOS was 
determined with qPCR using Taqman primer OTOS (Hs00964785_m1) and compared to 
mouse Act (Mn00607939_s1), the endogenous control. Comparative ΔΔCT method was 
used to determine fold change of human OTOS at each timepoint. Four independent 
experiments were performed and each sample was run in triplicate on a Life Technology 
Viia7 PCR machine.   
 
RESULTS 
 
Cohort Characteristics 
Of 1,029 TCS who passed GWAS QC criteria, 608 (59.1%), 265 (25.8%), and 154 (15.0%) 
reported none, mild, and moderate/severe tinnitus, respectively. Subjects were 
dichotomized to cases (moderate/severe) and controls (none). Two cases were excluded 
for inconsistent responses. Cohort characteristics are provided in Table 1. Median age at 
diagnosis and evaluation was 31 (15-54) years and 39 (18-75) years, respectively. Median 
follow-up time was 5.2 (1-37) years. 91.6% were treated with either BEP (n=444, 58.3%) 
or EP (n=254, 33.3%). The remaining 64 (8.4%) received vinblastine (n=6), carboplatin 
(n=5) or ifosfamide (n=45) in combination with cisplatin, or had missing cisplatin dose 
data (n=12).  
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Diagnosis and Treatment Risk Factors 
Cumulative cisplatin dose was significantly associated with tinnitus (OR per 100 
mg/m2=1.38, 95% confidence interval (CI): 1.1-1.7, P=0.007). Tinnitus risk for 400 mg/m2-
treated TCS (n=358) was not significantly greater than those receiving 300 mg/m2 (n=300) 
(OR=1.14, 95% CI: 0.8-1.6, P=0.41). However, survivors who received >400 mg/m2 (n=30, 
median dose=580 mg/m2, range=402-828 mg/m2) were at 2.61(95% CI: 1.8-3.9)-fold 
increased risk compared to those receiving ≤400 mg/m2 (P<0.0001, Figure 1A). Tinnitus 
was not associated with cumulative doses of bleomycin (OR=1.01, P=0.13), etoposide 
(OR=1.02, P=0.33), or ifosfamide (OR=1.06, P=0.87) when cumulative cisplatin dose was 
included as a covariate. Three of five TCS receiving both carboplatin (median dose=1800 
mg/m2, range=5-3,646 mg/m2) and cisplatin (median dose=200 mg/m2, range=200-527 
mg/m2) had tinnitus (OR=7.37, 95% CI: 1.2-58.5, P=0.034). Tinnitus was associated with 
increasing age at diagnosis as a continuous variable (OR by decade=1.31, 95% CI: 1.1-1.6, 
P=0.006) and by quartile (OR=1.22, P=0.013, Figure 1B). Age at evaluation was also 
associated with tinnitus (OR=1.30, 95% CI: 1.1-1.5, P=0.002). No association with follow-up 
duration was observed (age-adjusted OR=0.99, P=0.57). 
 
Associations with Self-Reported Health and Neuro-Ototoxic Symptoms 
Self-reported overall health was significantly lower in cases than in controls (OR=0.54, 
95% CI: 0.4-0.7, P<0.0001, Figure 2A). Tinnitus cases also reported using psychotropic 
medications more frequently than controls (OR=2.40, 95% CI: 1.3-4.4, P=0.003, Figure 2B). 
Audiometry was performed on 602 (78.4%) subjects. TCS with tinnitus had significantly 
worse hearing at every frequency examined (0.25 kHz-12 kHz, P<0.0001, Figure 3A). 
Tinnitus was also associated with self-reported hearing loss (OR=6.38, 95% CI: 4.9-8.5, 
P<0.0001, Figure 3B), problems hearing in a crowd (OR=8.28, 95% CI: 5.5-12.5, P<0.0001, 
Figure 3C), and persistent dizziness or vertigo (OR=6.40, 95% CI: 3.2-12.9, P<0.0001, 
Figure 3D), as well as symptoms of sensory neuropathy (OR range 1.66-2.72, P-
values<0.0001, Figure 3E). 
 
Associations with Modifiable Risk Factors 
Tinnitus was significantly associated with hypertension (age-adjusted OR=2.07, 95% CI: 
1.3-3.4, P=0.003), and hypercholesterolemia (age-adjusted OR=1.96, 95% CI: 1.2-3.2, 
P=0.009). In an age at clinical examination-adjusted model with both variables, tinnitus 
was significantly associated with hypertension (OR=1.77, 95% CI: 1.02-3.0, P=0.039), but 
not hypercholesterolemia (OR=1.6, 95% CI: 0.9-2.8, P=0.09). Tinnitus was associated with 
noise exposure at work (age-adjusted OR=1.93, 95% CI: 1.3-2.8, P=0.0005), and outside of 
work (age-adjusted OR=2.28, 95% CI: 1.6-3.3, P<0.0001). Risk was also associated with 
chronic (>15 years) smoking (age-adjusted OR=2.07, 95% CI: 1.2-3.8, P=0.005), but not 
increased among ever smokers (OR=1.26, 95% CI: 0.9-1.7, P=0.20) or with alcohol 
consumption (OR=0.92, 95% CI: 0.5-1.5, P=0.12). Association with chronic smoking 
remained significant after adjusting for age, hypertension, and noise exposure (OR = 1.79, 
95% CI: 1.01-1.04, P=0.04).  
 
Genome-Wide Association Study 
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Using GCTA’s linear mixed model approach (26), we found that additive SNP effects 
explained a large fraction of CisIT variance (h2=0.81±0.42, P=0.006). In GWAS, no SNP met 
genome-wide significance (Table S1, Figure S3). The first independent signal identified 
(rs7532231, OR = 0.45, P = 1.1x10-6) is 116 kilobases upstream of the lncRNA RP11-
364B6.1. The second (rs6671895, OR = 4.32, P = 1.2x10-6) is intronic to the lncRNA RP5-
884C9.2. The third (rs7606353, P=1.9x10-6, Figure 4A) is a SNP 14 kilobases downstream 
of OTOS (otospiralin), a gene implicated in auditory function and survival of cochlear 
fibrocytes (33, 34). This variant is in near perfect linkage disequilibrium with rs74002277 
in Europeans (CEU R2=0.96), a SNP in the 3’-UTR region of OTOS and which alters several 
transcription binding motifs (35). The minor allele (G, 4% frequency) increased CisIT risk 
(OR=4.20, 95% CI: 2.3-7.5). Since there has been prior evidence that OTOS protects 
cochlear fibrocytes against cisplatin cytotoxicity (36), we hypothesized that variants 
associated with higher OTOS expression lowered CisIT risk. In GTEx, OTOS was significantly 
expressed only in pituitary and thyroid tissues (Figure S4). We found that OTOS eQTLs 
were significantly enriched in GWAS independently from rs7606353 (P=0.018). One 
haplotype block containing six thyroid/pituitary eQTLs was driving this enrichment (Table 
S2, Figure S4). The minor allele (A) of the most significant variant within this block 
(rs10190781, 1.5% frequency) was associated with higher CisIT risk (OR=3.42, 95% CI: 
1.5-9.5, P=0.007, Figure 4B) and lower OTOS expression (Figure 4C), suggesting that 
higher OTOS expression is protective. Tinnitus risk increased with the number of risk 
alleles in either locus (OR=3.77, 95% CI: 2.3-6.2, P=9.5 x 10-8, Figure 4D).  
 
Functional Analysis 
We tested the association between OTOS expression and cellular sensitivity to cisplatin (as 
measured by area under the dose response curve) in central nervous system (CNS) tumor 
lines (30, 31) and found a significant positive correlation (Spearman Rho=0.46, P=0.03; R2 
= 0.25, P = 0.01, Figure 4E), further supporting a protective OTOS function against 
cisplatin-induced damage. To examine the specificity of this correlation, we compared the 
sensitivity of CNS tumor cell lines to eight antineoplastic agents (5-fluorouracil (5-FU), 
bleomycin, bortezomib, cisplatin, cytarabine, docetaxel, etoposide, and vinblastine) based 
on OTOS expression levels (Table S3). We also examined the relationship between cisplatin 
sensitivity and OTOS expression in seven cancer cell line types (aerodigestive, breast, CNS, 
digestive system, lung, skin, and urogenital system; Table S4). Of the cytotoxic drugs 
tested, only cisplatin sensitivity demonstrated a statistically significant correlation with 
OTOS expression in CNS lines. Further, cisplatin sensitivity was associated with OTOS 
expression only in CNS tumor lines and not cell lines of other tissue origins. These data 
suggest a CNS tumor-specific association between OTOS expression and cisplatin 
sensitivity. 
 
To functionally validate the role of OTOS gene expression in cellular sensitivity to cisplatin, 
we overexpressed OTOS in two cell lines, HEI-OC1 (a mouse auditory cell line) and L929 (a 
mouse fibroblast cell line), and compared gene expression levels and cellular proliferation 
following cisplatin treatment in OTOS-transfected cells and plasmid-transfected control 
cells (Figure 5A). Overexpression of human OTOS in HEI-OC1 resulted in increased cell 
viability following cisplatin treatment at 5, 7.5, 10, and 25 μM concentrations for 48 hours 
(P=0.004; Figure 5B) and 72 hours (P=0.008; Figure 5C). Figure S5 illustrates the effect of 
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cisplatin on HEI-OC1 cells transfected with human OTOS and plasmid control. Furthermore, 
the cisplatin IC50 value of HEI-OC1 cells transfected with human OTOS (18.68 μM, 95% CI: 
13.95-25.01 μM) was 1.8-fold higher than cells transfected with the control plasmid (10.66 
μM, 95% CI: 6.04-18.82 μM) at 48 hours. Overexpression of OTOS was confirmed via qPCR, 
with human OTOS expression increasing 69-fold at the time of drug treatment, 24 hours 
following pOTOS transfection (Figure 5C inset). Similarly, overexpression of OTOS in L929 
fibroblasts also markedly reduced cellular sensitivity to cisplatin following treatment for 
48 hours (P=0.006; Figure 5D) and 72 hours (P=0.03; Figure 5E) concomitant with 
increased expression of OTOS (Figure 5E inset).  The cisplatin IC50 value in OTOS-
transfected cells (16.30 μM, 95% CI: 13.25-20.04 μM) was 1.5-fold higher than cells 
transfected with the control plasmid (10.96 μM, 95% CI: 8.82-13.61 μM) at 48 hours. 
 
Pathway Analysis 
We mapped SNPs to genes by proximity and performed pathway enrichment with Gene 
Ontology terms. We identified 134 coding genes with P<5x10-4 (Table S5). Ten pathways 
were significantly over-represented (Table S6), including nervous system process (q = 
0.005), potassium ion transmembrane transport (q = 0.007), and sensory perception of sound 
(q = 0.005). Potassium transport most strongly implicated KCNQ1 (rs2283200, P = 8.9 x 10-
6), which maintains high potassium concentrations in the endolymph of the inner ear (37, 
38). 
 
 
DISCUSSION 
 
To our knowledge, this is the first investigation to consider the effects of clinical, genetic, 
and lifestyle factors on CisIT risk. Here 25.8% and 15.2% of cisplatin-treated TCS reported 
mild and moderate/severe tinnitus at a median of 5 years after treatment. Survivors 
treated with 100-400 mg/m2 cisplatin appeared to have similar CisIT risk, but those given 
>400 mg/m2 were at 2.6-fold increased risk, suggesting a non-linear threshold-dose 
response. Follow-up time was not associated with CisIT, suggesting irreversibility, but 
longitudinal data are needed to support this observation. Significant associations with 
tinnitus were observed for hearing loss, vertigo, sensory neuropathy, poorer overall health, 
and use of psychotropic medications, as well as for hypertension, noise exposure, and 
chronic smoking. GWAS revealed independent signals implicating OTOS that had relatively 
large effect sizes (ORs of 3.5-4.5) and were relatively rare (minor allele frequencies 1-5%). 
We verified protective effects of OTOS through eQTL analysis and functional validation in 
two cell lines, demonstrating that decreased OTOS expression increases susceptibility to 
CisIT. Whether thyroid/pituitary eQTLs co-regulate expression in cochlear fibrocytes is 
unknown, and human cochlear transcriptomic databases are necessary for more precise 
interpretations. However, we provide further evidence for OTOS’s protective functions in 
silico using central nervous system cell line data, and in vitro by overexpressing human 
OTOS in a mouse auditory cell line routinely used for in vitro drug ototoxicity screening 
(39) and a mouse fibroblast cell line. Pathway analysis implicated potassium transport 
genes, including the cochlear potassium transporter KCNQ1(37, 38). 
 
Research. 
on April 30, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3179 
12 
 
Treatment-Related Risk Factors 
Despite adequate statistical power, significant differences in tinnitus risk between TCS 
given 3 vs. 4 cycles of cisplatin-based chemotherapy were not evident. Brydøy et al. 
previously showed that TCS treated with >4 cycles of cisplatin-based chemotherapy had a 
2.21-fold increased risk of tinnitus compared with those given 1-4 cycles (40), consistent 
with our findings. Bokemeyer et al. showed a dose-dependent increased risk for ototoxicity 
after cisplatin-based chemotherapy, but did not specifically assess tinnitus or compare by 
dosage group (41).  
 
Modifiable Risk Factors  
An approximate 2-fold association between hypertension and CisIT was apparent among 
our TCS. The relationship between hypertension and tinnitus in the general population is 
well-established, with a recent meta-analysis estimating a pooled OR of 1.37 (P<0.05) (42). 
It has been hypothesized that hypertension causes damage to either the cochlear 
microcirculation and/or the stria vascularis, which supplies blood to the organ of Corti 
(43). This could explain the observed association. 
 
Multiple studies have identified a relationship between tobacco use and tinnitus in the 
general population (44-46) and we found a significantly increased risk of tinnitus in 
survivors with >15 years of tobacco use. It is possible that long-term tobacco use may 
reduce peripheral blood flow, including to the inner ear microcirculation. The role of 
tobacco use in CisIT was examined by Brydøy et al., but significant associations were not 
apparent for either current or former smokers compared with never smokers (40), similar 
to our results.  
 
Noise exposure is a known risk factor for tinnitus (47), but its role in the development of 
the hearing disorder in other cisplatin-treated cohorts has not been evaluated to our 
knowledge. Although Bokemeyer et al. reported an association between a history of noise 
exposure and cisplatin-induced ototoxicity, this term included both tinnitus and hearing 
loss (41). 
 
Sensory Neuropathy 
In our cohort, tinnitus was positively associated with symptoms of sensory neuropathy. 
This could suggest that inherent susceptibility to cisplatin-induced neurophysiological 
damage may partially underlie various neuro-otological symptoms, possibly involving 
pharmacokinetic pathways, intrinsic cisplatin sensitivity, reduced regenerative capacity, or 
altered neural plasticity. Another possible explanation is that of patient perception. Self-
reported tinnitus, hearing loss, and neuropathy in cancer survivors have been linked to the 
Impact of Events Scale-Revised (IES-R) hyperarousal scores (13), suggesting that 
differences in perception and appraisal could partially explain our findings. One study 
showed that audiometric thresholds correlated with tinnitus awareness time and loudness, 
but that tinnitus-induced annoyance was associated with proneness to exhibit anxious 
responses (48, 49). These investigations highlight how both cochlear and central nervous 
mechanisms contribute to tinnitus. 
 
Tinnitus Pathophysiology 
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While single-variant analysis did not identify significant genetic signals, we found that 
cumulatively, additive SNP effects explain a large portion of variance in CisIT, further 
supporting the hypothesis that CisIT is a polygenic trait with complex genetic 
underpinnings (4). Several mechanisms of tinnitus have been proposed, but no consensus 
on its etiology has been reached. One model postulates that disruptions to the 
endocochlear potential result in inhibitory-excitatory imbalances affecting spontaneous 
cochlear activity and lead to tinnitus (50). Inner-ear fibrocytes supply potassium ions to 
strial cells which pump them into the endolymph to maintain the endocochlear potential, 
the “cochlear battery” driving auditory transduction (51). The link between endocochlear 
potential and spontaneous auditory nerve activity has been established (52). Our GWAS 
points to the potential importance of this hearing mechanism in CisIT. 
 
OTOS mRNA and protein expression localize to spiral limbus and spiral ligament fibrocytes 
(33), and overexpression protects primary spiral ligament fibrocytes against cisplatin 
cytotoxicity (36). In support of the protective effect of OTOS against cisplatin sensitivity, 
our in silico analysis indicated that cisplatin sensitivity is positively associated with 
increased OTOS expression in CNS tumor cell lines, a rough approximation of cell types that 
would be affected by cisplatin-induced neurotoxicity. While CNS tumor cell lines are not an 
ideal proxy for assessing toxicity to inner ear cells, we further validated the protective 
effects of OTOS by demonstrating that its overexpression in vitro reduces cisplatin 
sensitivity in two cell lines (HEI-OC1 and L929), with HEI-OC1 more accurately reflecting 
inner ear cells that are adversely affected by cisplatin.  
 
In support of our findings, two prior studies have elucidated the importance of OTOS 
expression in mammalian hearing. Inducible knockdown of OTOS in guinea pigs caused 
severe degeneration of the organ of Corti and deafness, along with damage to fibrocytes 
(33). Interestingly, although Otos –/– mice had damaged fibrocytes, they did not exhibit 
histological abnormalities of sensory hair cells, and experienced only moderate deafness 
(34). Delprat et al. attributed this difference to long-term adaptation to congenital Otos 
absence (33). Therefore, it is plausible that inducible knockdown, modeling key aspects of 
direct auditory insults such as cisplatin administration, will acutely alter the ionic 
composition of the endolymph, disrupting hair cell metabolism and survival. 
 
Breglio et al. recently showed a reduction of endocochlear potential following cisplatin 
administration in mice, and preferential accumulation of cisplatin in the stria vascularis 
(53). We linked potassium transport to CisIT in our pathway analysis, which most strongly 
implicated KCNQ1, an important cochlear ion channel. This voltage-gated channel localizes 
to marginal cells of the stria vascularis where it maintains high K+ concentrations in the 
endolymph (37). Mutations in KCNQ1 result in deafness and long QT syndrome (54).   
 
Taken together, these findings point to the function of supporting cells in the cochlear 
lateral wall in cisplatin ototoxicity and hair cell survival. Impaired maintenance of the 
endolymph causes hair cell death and permanent hearing loss (55), which may be partially 
mediated by a reduced endocochlear potential. However, prior research has largely focused 
directly on cisplatin’s cytotoxic mechanisms in hair cells (56). Our new findings, together 
with those in the literature, suggest that novel strategies aimed at protecting supporting 
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cells in the cochlear lateral wall, perhaps by stimulating OTOS expression, may prove 
beneficial. Very little is known about the protein product of the gene, its functions, and its 
interactions. Better understanding of the functional protein and its cellular localization and 
interactions is warranted. A potential approach would be to use a gene expression-based 
high throughput screen to identify small molecules or siRNA capable of markedly 
increasing OTOS expression without perturbing the viability of auditory cells, such as HEI-
OC1. The identification of compounds or siRNAs resulting in increased OTOS expression 
could be evaluated for their effect on protecting cells from cisplatin damage. Importantly, 
the utility of this approach depends on the modulation not impacting the antineoplastic 
activity of cisplatin. 
 
It remains unclear whether the effects of OTOS on tinnitus occur directly or are mediated 
by effects on hearing loss. However, if OTOS protects against tinnitus indirectly by 
preventing hearing loss, it remains a viable candidate for cisplatin otoprotection. It is also 
unclear whether the actions of OTOS are uniquely pertinent to cisplatin or generalizable to 
other ototoxic insults like noise, although evidence of direct protection against cisplatin 
cytotoxicity is presented here and in the literature (36). Future studies should elucidate the 
cellular functions and interactions of otospiralin to assess its viability as a target for 
cisplatin otoprotection. 
 
CONCLUSIONS 
Strengths of our study include the collection of detailed treatment data, homogeneous 
cisplatin-based chemotherapy, long-term follow-up, quantitative hearing evaluations, the 
use of validated instruments to assess neurotoxic symptoms, and the novel implementation 
of genome-wide scans to nominate cellular mechanisms and targets. Our results point to 
cochlear mechanisms that have not yet been widely explored in cisplatin ototoxicity, and 
may provide novel opportunities for targeted otoprotection.  
 
An intrinsic limitation of all cross-sectional studies is the inability to make causal 
inferences. Further, questionnaires with more detailed information on the experience of 
tinnitus, including baseline measurements pre-chemotherapy, would provide more 
conclusive evidence with regard to associations noted here. However, given the young 
median age of patients at treatment, it is unlikely that tinnitus was pre-existing. It is 
important to note that the results of our translational research could potentially impact 
millions of patients worldwide annually diagnosed with cisplatin-treated cancers who are 
at risk for CisIT. Our findings may also inform tinnitus research in non-platinum-treated 
patients. In view of our results, health care providers can improve management of cancer 
survivors experiencing CisIT by recommending monitoring of blood pressure, 
encouragement of smoking cessation, and avoidance of additional ototoxic insults such as 
noise exposure.  
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Table 1. Demographic Features, Clinical Characteristics, and Patient-Reported Outcomes of 762 
Male Germ Tumor Survivors According to Tinnitus Status 
Characteristic 
All Participants 
(n=762) 
Tinnitus Controls 
(n=608) 
Tinnitus Cases
a
 
(n=154) 
Age at diagnosis (years)
b 
   Median (range) 31 (15-54) 30 (15-54) 35 (16-52) 
   <20 43 (5.7%) 35 (5.8%) 8 (5.2%) 
   20-29 300 (39.8%) 249 (41.5%) 51 (33.1%) 
   30-39 243 (32.2%) 196 (32.7%) 47 (30.5%) 
   40-55 168 (22.2%) 120 (20.0%) 48 (31.2%) 
Age at assessment (years) 
   Median (range) 39 (18-75) 38 (18-71) 43 (20-75) 
   <20 6 (0.8%) 5 (0.8%) 1 (0.6%) 
   20-29 134 (17.6%) 115 (18.9%) 19 (12.3%) 
   30 to 49 274 (36.0%) 230 (37.8%) 44 (28.6%) 
   40 to 49 202 (26.5%) 150 (24.7%) 52 (33.8%) 
   50 to 59 123 (16.1%) 88 (14.5%) 35 (22.7%) 
   ≥60 23 (3.0%) 20 (3.3%) 3 (2.0%)  
Time since therapy completion (years)
c 
   Median (range) 5.2 (1-37) 5.1 (1-37) 6.2 (1-35) 
≤1 3 (0.4%) 1 (0.2%) 2 (1.3%) 
>1 and ≤5 362 (48.0%) 293 (48.8%) 69 (44.8%) 
>5 and ≤10 180 (23.9%) 145 (24.2%) 35 (22.7%) 
>10 and ≤20 159 (21.1%) 127 (21.2%) 32 (20.8%) 
>20 50 (6.6%) 34 (5.7%) 16 (10.4%) 
Educational level    
   Secondary school or less 95 (12.6%) 62 (10.3%) 33 (21.9%) 
   Post-secondary school training 166 (22.0%) 129 (21.4%) 37 (24.5%) 
   College graduate 334 (44.2%) 276 (45.7%) 58 (38.4%) 
   Post graduate training/degree 160 (21.2%) 137 (22.7%) 23 (15.2%) 
Chemotherapy regimen
d
    
   BEP 444 (58.3%) 355 (58.4%) 89 (57.8%) 
   EP 254 (33.3%) 205 (33.7) 49 (31.8%) 
   Other 64 (8.4%) 48 (7.9%) 16 (10.4%) 
Number of cycles, platinum-based chemotherapy
e
   
   ≤2 15 (2.0%) 13 (2.2%) 2 (1.3%) 
   3 333 (44.0%) 272 (45.1%) 61 (39.6%) 
   4 389 (51.4%) 307 (50.9%) 82 (53.2%) 
   >4 20 (2.6%) 11 (1.8%) 9 (5.8%) 
Cumulative cisplatin dose (mg/m
2
)
f 
  
   Median 400 (100-828) 400 (200-800) 400 (100-827.6) 
   < 300 41 (5.5%) 32 (5.4%) 9 (5.9%) 
   300 300 (40.0%) 248 (41.5%) 52 (34.0%) 
   >300 and <400 21 (2.8%) 15 (2.5%) 6 (3.9%) 
   400 358 (47.7%) 287 (48.1%) 71 (46.4%) 
   > 400 30 (4.0%) 15 (2.5%) 15 (9.8%) 
Reduced hearing in past four weeks
g
   
   Not at all 555 (73.1%) 521 (85.7%) 34 (22.5%) 
   A little 127 (16.7%) 71 (11.7%) 56 (37.1%) 
   Quite a bit/very much 77 (10.1%) 16 (2.6%) 61 (40.4%) 
Problems hearing in crowds
h
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Characteristic 
All Participants 
(n=762) 
Tinnitus Controls 
(n=608) 
Tinnitus Cases
a
 
(n=154) 
   Yes
 
222 (30.6%) 124 (21.2%) 98 (69.0%) 
   No 505 (69.4%) 461 (78.8%) 44 (31.0%) 
Requires hearing aid
i
    
   Yes
 
2 (0.3%) 2 (0.3%) 0 (0%) 
   No 741 (99.7%) 602 (99.7%) 139 (100%) 
Noise exposure    
   None 430 (56.4%) 365 (60.0%) 65 (42.2%) 
   Work related OR other exposure 213 (28.0%) 163 (26.8%) 50 (32.5%) 
   Work related AND other exposure 119 (15.6%) 80 (13.2%) 39  (25.3%) 
Audiometrically assessed hearing loss
j,k
   
   None/mild 238 (39.4%) 220 (45.4%) 18 (15.0%) 
   Moderate 93 (15.4%) 75 (15.5%) 18 (15.0%) 
   Moderately severe 129 (21.4%) 103 (21.3%) 26 (21.7%) 
   Severe/profound 144 (23.8%) 86 (17.8%) 58 (48.3%) 
Peripheral neuropathy
l
    
   None 373 (49.0%) 329 (54.1%) 44 (28.6%) 
   Mild 281 (36.9%) 215 (35.4%) 66 (42.9%) 
   Severe 108 (14.1%) 64 (10.5%) 34 (28.6%) 
Persistent vertigo or dizziness
m
    
   Yes 36 (4.9%) 15 (2.5%) 21 (14.3%) 
   No 702 (95.1%) 576 (97.5%) 126 (85.7%) 
Self-reported health
n
    
   Excellent
 
134 (17.6%) 121 (20.0%) 13 (11.7%) 
   Very good 317 (41.7%) 264 (43.6%) 53 (45.5%) 
   Good 266 (35.0%) 196 (32.3%) 70 (34.4%) 
   Poor/fair 43 (5.7%) 25 (4.1%) 18 (8.4%) 
Medication for anxiety, psychosis, and/or depression
o
   
   Yes 57 (10.1%) 38 (8.3%) 19 (17.75%) 
   No 510 (89.9%) 422 (91.7%) 88 (82.2%) 
Hypertension and on medication    
   Yes 106 (14.0%) 69 (11.6%) 37 (24.2%) 
   No 651 (86.0%) 535 (89.9%) 116 (75.8%) 
Smoking status
p
    
   Ever smoker
 
303 (39.9%) 235 (38.8%) 68 (44.2%) 
   Never smoker 457 (60.1%) 371 (61.2%) 86 (55.8%) 
Alcohol consumption
q
    
   ≤4 drinks per week
 
487 (64.2%) 384 (63.4%) 103 (66.9%) 
   5-7 drinks per week 172 (22.7%) 140 (24.3%) 32 (20.8%) 
   ≥2 drinks per day 100 (13.2%) 81 (12.3%) 19 (12.3%) 
Abbreviations: BEP, bleomycin, etoposide, and cisplatin, EP, etoposide, and cisplatin, NA not applicable 
 
NOTE: Data presented as number (%) unless otherwise noted  
a Restricted to patients who reported “quite a bit’ or ‘very much” tinnitus. Patients who reported “a little” tinnitus 
(n=265) are excluded from the table and all analyses. 
b Category excludes 8 participants for whom age at diagnosis was not recorded.  
c Category excludes 8 participants for whom this variable was not stated.  
d BEP category includes patients who received only bleomycin, etoposide, and cisplatin; EP includes patients who received 
only etoposide and cisplatin. The other category includes patients who received other antineoplastic agents, including 
ifosfamide (n=45), vinblastine (n=6), and carboplatin (n=5), or who were missing dose data (n=12). 
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e Category excludes 5 participants for whom number of cycles was not stated. 
f Category excludes 12 participants for whom complete dose data were not available.  
g Category excludes 3 participants who did not answer this question. 
h Category excludes 35 participants who did not answer this question. 
i Category excludes 19 participants who did not answer this question. 
j Category excludes 158 participants who did not complete audiometric testing.  
k ASHA criteria defined hearing loss severity as the following: mild: 21 to 40 dB; moderate: 41 to 55 dB; moderately 
severe: 56 to 70 dB; severe: 71 to 90 dB; and profound: > 90 dB; for at least one tested frequency for either ear 
(https://www.asha.org/public/hearing/Degree-of-Hearing-Loss) 
l Following conversion of the Likert scale: “none, a little, quite a bit, very much” to a 0-3 numeric scale, each individual 
was assigned a summary statistic for the sensory subscale (Cronbach (α = 0.88) and the motor subscale (α = 0.78) by 
taking the mean of the response in the subscale: none (mean = 0), mild (0 < mean ≤ 1), severe (mean > 1)  (16, 17). 
m Category excludes 24 participants who did not answer this question. 
n Category excludes 2 participants who did not answer this question. 
o Category excludes 195 who did not answer this question. Participants could report more than one psychotropic 
medication including anxiolytics, antipsychotics, and antidepressants. Psychotropic medications investigated include: 
alprazolam (n=8), aripiprazole (n=2), amphetamine + dextroamphetamine (n = 14), amantadine (n = 1), buproprion (n = 
9), carbidopa/levodopa (n = 1), citalopram (n = 8), clonazepam (n = 13), desvenlafaxine (n = 1), diazepam (n = 1), 
duloxetine (n = 8), escitalopram (n = 19), fluoxetine (n = 5), fluvoxamine (n = 1), hydroxazine (n = 1), lisdexamfetamine (n 
= 4), lorazepam (n = 1), methylphenidate (n = 13), nortriptyline (n = 2), olanzapine (n = 2), paroxetine (n = 5), pramipexole 
(n = 1), sertraline (n = 7), trazodone (n = 8), valproate (n = 1), venlafaxine (n = 10). 
p Category excludes 2 participants for whom this outcome was not stated. 
q Category excludes 3 participants for whom this outcome was not stated. 
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FIGURE LEGENDS 
 
Figure 1. Tinnitus Frequency by Cumulative Cisplatin Dose and Age at Testicular 
Cancer Diagnosis (quartiles). A. Bar plot showing the frequency of tinnitus by cumulative 
cisplatin dose group (<300, 300, 400, and >400 mg/m2) illustrates that the significant 
association between dose and tinnitus (logistic regression OR = 1.38, 95% CI: 1.1-1.7, 
P=0.007) is due to the significantly increased risk of tinnitus in patients treated with doses 
> 400 mg/m2 (post-hoc Chi-squared P < 0.0001). The number of subjects per category is 
presented on the x-axis under the dose group label. B. Bar plot representing the frequency 
of tinnitus by age at diagnosis quartile shows positive association with cisplatin risk (OR by 
decade = 1.31, 95% CI: 1.1-1.6, P = 0.006). Error bars represent the binomial 95% CIs for 
each subgroup. N.S = not significant. 
 
 
Figure 2. Self-reported Health and Use of Psychotropic Medications by Tinnitus 
Status. A. Bar plot of the distribution of self-reported health according to tinnitus status. 
Patients were asked: “How would you rate your overall health?” and responded on a poor-
excellent ordinal scale, which was converted to a numeric scale (0 = poor/fair, 1 = good, 2 = 
very good, 3 = excellent). Logistic regression revealed significant negative correlation 
between tinnitus status and self-reported health (OR=0.54, 95% CI: 0.4-0.7, P<0.0001). B. 
Bar plot of psychotropic medication use by tinnitus status shows significantly higher 
prevalence of psychotropic medication use in tinnitus cases (OR= 2.4, 95% CI: 1.3-4.4, 
P=0.003). Patients were dichotomized to “Yes” and “No” psychotropic medication use 
based on receiving medications from a list of frequently prescribed antidepressants, 
anxiolytics, and antipsychotics (Supplemental Methods, (15)). The number of subjects per 
category is presented on the x-axis. Error bars represent the binomial 95% CIs for each 
subgroup. 
 
 
Figure 3. Associations of Tinnitus with Subjective and Objective Hearing Loss, 
Problems Hearing, Vertigo, and Neurological Symptoms. A. Box plot of audiometric 
hearing thresholds (y-axis, dB) across all tested audiometric frequencies (x-axis, kHz) 
showing significantly worse hearing in tinnitus cases at each frequency (P < 0.0001 at each 
frequency). Box centers indicate medians, hinges indicate interquartile regions (IQRs), and 
whiskers indicate 1.5x IQRs. Points outside the range of 1.5x IQR are shown. Bar plots of 
self-reported B. difficulty hearing (OR = 6.36, 95% CI: 4.8-8.5, P < 0.0001), C. problems 
hearing in a crowd (OR = 8.2, 95% CI: 5.5-12.5, P<0.0001), and D. persistent dizziness or 
vertigo (OR = 6.40, 95% CI: 3.2-12.9, P<0.0001). Error bars represent the binomial 95% CIs 
for subgroup. E. Forest plot showing the odds ratio (OR, center points) and 95% confidence 
intervals (error bars) of the association between tinnitus and neurotoxic symptoms from 
the EORTC-CIPN20. “H” denotes hands/fingers. “F” denotes feet/toes. Responses to EORTC-
CIPN20 items were converted from a none-very much Likert scale to a numerical ordinal 
scale (0-3). Associations in B-E were evaluated using logistic regression adjusted for age at 
diagnosis. 
 
 
Research. 
on April 30, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3179 
26 
 
Figure 4) GWAS of Cisplatin-Induced Tinnitus Reveals Genetic Loci Near OTOS gene. 
A. LocusZoom plot of the third most significant GWAS signal near two adjacent genes: OTOS 
and MYEOV2. Each point represents a SNP. The x-axis indicates chromosomal position. The 
left y-axis shows –log10(p-value) of association with CisIT and the right y-axis and blue line 
indicate the recombination rate in centimorgans/megabase (cM/MB). The color of each 
variant indicates the linkage disequilibrium R2 with the top signal in the region, rs7606353 
(purple). B. Bar plot of CisIT frequency by genotype of OTOS eQTL, rs10190781. The minor 
allele (G) increases CisIT risk (OR = 3.42, P = 0.007). Error bars represent the binomial 95% 
CIs. C. Boxplot of OTOS expression in thyroid by rs10190781 genotype indicates that the 
minor allele is associated with lower expression of OTOS. Data were obtained from the 
GTEx Portal on 04/28/18 D. Bar plot of number of risk alleles for both rs7606353 and 
rs10190781 shows additive allele effects (OR = 3.77, 95% CI: 2.3-6.2], P=9.5 x 10-8. E. 
Scatter plot of cisplatin resistance as a function of normalized OTOS expression. Cisplatin 
resistance, measured as the area under the cisplatin dose-response curve, for all central 
nervous system tumor lines (19 glioma and 4 neuroblastoma lines) was extracted from 
CancerRX and normalized OTOS expressions were downloaded from the Cancer Cell Line 
Encyclopedia. Correlation was assessed non-parametrically using Spearman’s Rank method 
(Rho = 0.46, P = 0.03).  
 
Figure 5) Effects of OTOS Overexpression on Cisplatin Sensitivity in HEI-OC1 Mouse 
Cochlear and L929 mouse fibroblast cell lines. A. Experimental scheme of transfection 
and cisplatin treatment, followed by cell viability and qPCR analysis. Cells were transfected 
with human OTOS (pOTOS) or a control plasmid (pControl) for 24 hours prior to cisplatin 
treatment. B. Cell viability of HEI-OC1 cells transfected with either pOTOS (closed circles) 
or the control plasmid (pControl; open circles) following treatment with increasing 
concentrations of cisplatin for 48 hours (P=0.004) or C. 72 hours (P=0.008). Inset: Human 
OTOS mRNA expression in HEI-OC1 cells corresponding to 0, 24, 48, and 72 hours after 
cisplatin treatment (24, 48, 72, and 96 hours after transfection) depicted as pOTOS relative 
to pControl. D. Cell viability of L929 fibroblasts transfected with either pOTOS (closed 
circles) or the control plasmid (pControl; open circles) following treatment with increasing 
concentrations of cisplatin for 48 hours (P=0.006) or E. 72 hours (P=0.03). Inset: Human 
OTOS mRNA expression in L929 fibroblasts corresponding to 0, 24, 48, and 72 hours after 
cisplatin treatment (24, 48, 72, and 96 hours after transfection) depicted as pOTOS relative 
to pControl. Data shown are from 3 independent experiments, with each concentration or 
time point within an experiment evaluated in duplicate or triplicate. Error bars reflect 
S.E.M. Statistical significance was determined using 2-way ANOVA analysis with Sidak 
correction for multiple comparisons. 
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